Key result
Nonsteroidal MR antagonists like finerenone improve safety and show anti-inflammatory effects for potential metabolic use.
Why the study?
Clinical translation of mineralocorticoid receptor antagonists has shown inconsistent outcomes and safety concerns in individuals with overweight or obesity, questioning whether MR remains a valid target for metabolic disorders.
Does targeting mineralocorticoid receptors with antagonists improve metabolic outcomes in obesity and metabolic syndrome?
Does targeting mineralocorticoid receptors with antagonists improve metabolic outcomes in obesity and metabolic syndrome?
Nonsteroidal mineralocorticoid receptor antagonists like finerenone may offer a safer therapeutic avenue for treating obesity and metabolic syndrome by targeting adipocyte dysfunction.
Answers are grounded in this paper and cite their sources.
Does not support practice change in metabolic disorders; leaves open need for RCTs to validate nonsteroidal MR antagonists.
The mineralocorticoid receptor (MR), classically known for its role in electrolyte homeostasis, has emerged since the early 2000s as a key regulator of adipocyte biology. MR activation induces oxidative stress and inflammation, promotes white adipogenesis, and suppresses brown fat differentiation, potentially contributing to obesity and metabolic syndrome (MetS). In mice, MR antagonists (MRAs) have shown beneficial metabolic effects by reversing adipose tissue dysfunctions, counteracting excessive expansion of fat depots and enhancing brown adipose tissue (BAT) thermogenesis. Clinical translation remains limited, with inconsistent outcomes in individuals with overweight or obesity, and concerns about side effects of steroidal MRAs (sMRAs), particularly hyperkalemia. Nevertheless, recent data showed that MRAs are able to activate BAT in healthy subjects and in patients with familial partial lipodystrophy type 2 (FPLD2). Nonsteroidal MR antagonists (nsMRAs), such as finerenone, exhibit anti-inflammatory and anti-fibrotic properties in the kidney and heart, with improved safety profiles compared to steroidal MR antagonists (sMRAs), and are currently explored in metabolic disorders beyond cardiorenal disease. This review summarizes novel insights into MR function in adipose tissue and critically evaluates whether MR can still be considered a valid target to treat obesity and associated metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Armani et al. (2026) studied this question. Nonsteroidal MR antagonists like finerenone improve safety profiles and exhibit anti-inflammatory effects, supporting their exploration in metabolic disorders.
Synapse has enriched 10 related papers. Consider them for comparative context: